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Dispositional mindfulness can be described as the mental ability to pay attention to the pres-
ent moment, non-judgmentally. There is evidence of inverse relation between dispositional
mindfulness and insomnia and substance use, but as of yet, no studies evaluating the spe-
cific association between dispositional mindfulness and the components of hypnotic use
disorder.
Objective
To evaluate the association between dispositional mindfulness and the components of
dependence among female chronic hypnotic users.
Design and method
Seventy-six women, chronic users of hypnotics, who resorted to Mindfulness-Based
Relapse Prevention for the cessation of hypnotic use were included in the study. The Five
Facet Mindfulness Questionnaire (FFMQ) evaluated the levels and facets of mindfulness,
and the subscales of the Benzodiazepine Dependence Questionnaire (BENDEP) assessed
dependence on hypnotics. We also evaluated sociodemographic variables and symptoms
of insomnia and anxiety. The associations between the FFMQ facets and the BENDEP
subscales were evaluated with binomial logistic regression, adjusted for income, schooling,
anxiety, and insomnia.
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Results
We observed associations between facets of the FFMQ and specific aspects of hypnotic
dependence. The facet “observing” was inversely associated with the “concern about lack of
availability of the hypnotic” [aOR = 0.87 95% CI (0.79–0.97)], and the facet “non-reacting to
inner experience” with “noncompliance with the prescription recommendations” [aOR = 0.86
95% CI (0.75–0.99)]. The total score of the FFMQ was inversely associated to those two
dependence subscales [aOR = 0.94 95% CI (0.89–0.99)]. “Observing” and “non-reactivity to
inner experience” were also inversely associated with the “impairments related to the with-
drawal symptoms” [aOR = 0.84 95% CI (0.73–0.97)] and [aOR = 0.78 95% CI (0.63–0.96)],
respectively. The FFMQ was not associated with “awareness of problematic hypnotic use”.
Conclusion
Dispositional mindfulness, specifically the facets “observing” and “non-reactivity to inner
experience, were inversely associated with the components of hypnotic dependence related
to the anticipation of having the substance, its expected effect, and the impairments caused
by the abstinence. We discuss the implications of those results for the clinical practice and
future investigations.
Introduction
Hypnotics, mainly benzodiazepines (BZD), are the most highly prescribed class of psycho-
pharmacological medication worldwide [1]. They are the leading prescription in Brazil,
with an especially high number of prescriptions among women [2]. The use of BZD for the
treatment of primary disorders such as sleep disturbances and anxiety for more than four
weeks, even in therapeutic doses, can cause cognitive problems, psychomotor and memory
impairment, in addition to tolerance, dependence and withdrawal syndrome [3]. Following
advancement in research on the deleterious effects of benzodiazepines, prescriptions for hyp-
notics other than benzodiazepines, such as zolpidem, zopiclone and ezopiclone (known as z
drugs), began to rise. As these are newer drugs, and subject of fewer studies, their long-term
deleterious effects are unclear. However, since their mechanism of action is quite similar to
that of benzodiazepines (GABA-A agonists, although not specific of the benzodiazepine site)
[4], further studies are required to evaluate the risks associated to consumption. There are
already reports in the literature suggesting acute cognitive side effects of z drugs [5] and that
continuous exposure to z drugs, as well as to benzodiazepines, significantly increase the odds
of mortality, even when adjusted for other mortality factors [6, 7]. The term “hypnotics” will
be used in this study as a reference to both classes of medication, indiscriminately.
Studies suggest a belief among physicians that hypnotics do not cause serious damage, and
lead to dependence only when used at high doses. There is a perceived lack of time and of
pharmacological alternatives to treat insomnia patients; therefore, many prescribers believe
hypnotics are one of the few treatment options [8]. Consequently, although most use is in
accordance with a prescription, medical supervision may not include knowledge of or infor-
mation given regarding the risks of prolonged use. This may lead to chronic consumption,
based on patient belief that it is safe [9]. Moreover, as the association among insomnia, anxiety
and daytime hyperarousal is frequent [10], psychological and cognitive factors also foster
chronic use. For instance, anticipation of negative effects due to a bad night of sleep on
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daytime functioning leads to higher levels of anxiety that may in turn lead to preoccupation
about the availability of the hypnotic, and even to the use of a higher dose [11]. Similarly, intol-
erance to the withdrawal symptoms when the medication is discontinued increases risk of
chronic use [12].
One of the few instruments that considers these important components of hypnotic
dependence is the Benzodiazepine Dependence Questionnaire (BENDEP-SRQ), which
defines dependence as having four components: (1) Problematic use, (2) Preoccupation
with the availability of the medicine, (3) Lack of compliance with the prescription, and (4)
Impairments caused by withdrawal. The subscales “Preoccupation” and “Lack of compli-
ance” both assess anticipatory anxiety, or thoughts of potential consequences of running
out of, not using, or not having a high enough dose of the medication. In populations with
higher levels of anxiety, these anticipatory thoughts may foster: 1) excessive and uncontrol-
lable concern in the form of ruminating thoughts that perpetuate and increase anxiety, lead-
ing to a “descending spiral”; 2) compulsive or automatic actions to alleviate anxiety, often
accompanied by self-judgment which may also perpetuate the descending spiral [13, 14].
Individuals often believe these cognitions and behaviors are productive, thus sustaining
cycles of use [15].
Awareness of the role that cognitive patterns, such as anticipatory anxiety, play in the onset
and maintenance of insomnia, and a kinder attitude towards discomfort caused by these
thoughts, or by withdrawal symptoms from reduction/removal of the hypnotic, might contest
the avoidance-based coping patterns [16] fostering alternative and effective coping responses
[17]. Mindfulness may be a valuable skill for individuals who present those symptoms. Mind-
fulness includes metacognitive ability described as “paying attention in a particular way; on
purpose, in the present moment, and non-judgmentally" [18]. Through mindfulness training,
this innate ability can be strengthened [19].
The practice of mindfulness was initially incorporated into the Western medicine as a
complementary approach to help patients better handle stress, chronic pain, and other clinical
conditions [18]. Literature on mindfulness for other conditions as insomnia, anxiety, and sub-
stance use is quickly growing [20–22]. Higher levels of dispositional mindfulness (innate abil-
ity or psychological trait) fosters a better relation with the cognitive or physical discomfort,
resulting from those disorders [23]. In populations with anxiety and substance dependence,
mindfulness increases awareness of triggers of automatic reactions, such as anticipatory rumi-
nation [24] or substance use [25], and trains individuals to disengage from unhelpful thoughts,
thus allowing them have more skillful choices to cope with challenges [26].
Several questionnaires aim to evaluate levels of dispositional mindfulness. Recent studies
have used measures to evaluate components of the mindfulness, encompassing not only atten-
tion, but also non-judgment, non-reactivity, and openness to the experience [27]. Among
these measures, the Five Facet Mindfulness Questionnaire (FFMQ), evaluating five components
of mindfulness [28], is one of the most widely used. It has been validated in several countries
[29–33], including Brazil [34].
The objective of the current cross-sectional study was to evaluate the association between
dispositional mindfulness and insomnia in treatment seeking female hypnotics users. Specifi-
cally, the study assessed facets of mindfulness and their relation to components of hypnotic
dependence assessing anticipation of availability or effects of hypnotics. In line with previous
studies evincing a negative association between mindfulness facets and psychiatric symptoms
[35], our hypotheses were that mindfulness, specifically the “observing” and “non-reactivity”
facets, would be inversely associated with the subscales of hypnotics dependence assessing the
anticipatory component, and the impairments caused by withdrawal.
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Materials and method
Participants
The sample of the present cross-sectional study used data from a randomized clinical trial eval-
uating the efficacy of a Mindfulness-Based Relapse Prevention (MBRP) on reduction of hyp-
notic use among female chronic users (ClinicalTrials.gov Identifier: NCT02127411). The
sample was composed of women residing in Sao Paulo, Brazil, recruited via print and digital
media, radio, and television. Recruiting and selection used the following inclusion and exclu-
sion criteria:
Inclusion criteria
• Adult women, over 18 years of age, able to read and write in Portuguese
• Use of hypnotic medication for sleep induction for at least three months (90 days), at least
four times a week, as assessed by a questionnaire assessing the pattern of hypnotics use.
Exclusion criteria
• Presence of neurologic conditions, cancer, anxiety refractory to other treatments, base psy-
chiatric disorders, secondary insomnia or other severe clinical conditions for which cessa-
tion of the hypnotic would present risk of worsening
• Dependence on or abuse use of alcohol or other drugs, except tobacco
• Undergoing acute treatment for psychological or psychiatric disorders
• Current participation in a program or protocol for hypnotic cessation
• Engagement in yoga, meditation, or other contemplative practices in the six months prior to
data collection
Interested individuals (234) underwent a brief phone screening. Of 234 respondents, 118
women did were deemed ineligibility due to: chronic use of hypnotics (n = 55); engagement in
contemplative practices in past six months (n = 29); participation in psychiatric treatment for
acute depression, panic disorder, bipolar disorder, substance dependence or generalized anxi-
ety (n = 18); lack of time or availability to participate in research activities (n = 12); or declined
participation but did not provide a reason (4).
In the second phase of the screening, the remaining 116 potentially eligible women were
referred to a psychiatric consultation. Exclusions in this phase were predominantly due to a
clinical condition that could destabilize with the withdrawal of the hypnotic, resulting in a
final baseline sample of 76 participants. See Fig 1 for recruitment flow diagram.
Procedures
After screening, eligible participants were invited to the Universidade Federal de São Paulo
(UNIFESP) for data collection. The current cross-sectional study used paper-and-pencil self-
report data collected at baseline in the presence of one research team member. The question-
naire battery took approximately 50 minutes to complete. Baseline data collection occurred
between August 2014 and October 2015.
We conducted this study in accordance with the Declaration of Helsinki, and the Commit-
tee of Ethics in Research (CER) of the Universidade Federal de São Paulo approved all the pro-
cedures (CAAE: 53377116.7.0000.5505). Participants were informed on the risk of discomfort
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while filling out some of the questionnaires, and compensation in the form of a free 16-hour
mindfulness course. All the participants signed an informed consent form.
Instruments. After being screened into the study, participants answered a sociodemo-
graphic questionnaire assessing age, education, family income, marital status, who they live
with, profession, menopause status, and medical supervision of hypnotics use. Additionally,
they answered the following structured questionnaires:
Dependence on hypnotics. Dependence on hypnotics was evaluated by the Benzodiaze-
pine Dependence Self-Report Questionnaire Portuguese Version (BENDEP-SRQ-PV) Ques-
tionnaire, short Portuguese version, translated and adapted to Brazilian Portuguese, under
validation by the authors of the present study. The scale evaluates the level of perception users
have of their dependence, using four subscales (terms in parentheses will henceforth be used
for abbreviation): Problematic use (Problematic use), or level of awareness of the problematic
use (α = 0.54); Preoccupation about the availability (Preoccupation), or level of concern/obses-
sion about the availability of the hypnotic (α = 0.61); Lack of compliance with the prescription
(Lack of compliance), or level of lack of compliance with the therapeutic regimen (α = 0.63);
and impairments induced by the withdrawal of the medication (Withdrawal) or level of certainty
in relation to the damage perceived associated with withdrawal symptoms (α = 0.68) [36]. All
the items are evaluated on a five-point Likert scale.
Fig 1. Flowchart of the study procedures.
https://doi.org/10.1371/journal.pone.0194035.g001
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Dispositional mindfulness. The Five Facet Mindfulness Questionnaire (FFMQ) [28] has
been validated in Brazil [34] and has shown good internal consistency (α = 0.81, in this sample
α = 0.85). It consists of 39 items on a five-point Likert scale that ranges from “Never or rarely
true” to “Very often or Always true”. The Brazilian version comprises seven factors that evalu-
ate five domains of Mindfulness. The factors and Cronbach’s α coefficients of this sample were
as follows: a) Observing (8 items): perception of internal and external experiences such as sen-
sations, cognitions, emotions, sights, sounds and smells (α = 0.79); b) Describing (8 items):
capacity of naming inner experiences, with positive and negative formulation in the Brazilian
version (positive α = 0.78; negative α = 0.83; c) Non-reactivity to inner experiences (7 items):
perception of thoughts and feelings without engaging in or being carried away by them
(α = 0.73); d) Acting with awareness (8 items): capacity of being focused on the activities of
the moment as opposed to the “automatic pilot”, that is, engaging mechanically in activities
while having attention focused elsewhere. In the Brazilian validation, items in this factor were
further divided into two subfactors, one with items related to automatic pilot (α = 0.80) and
the other with items related to distraction (α = 0.73); e) Non-judging of inner experience (8
items): related to not evaluating and judging feelings and thoughts (α = 0.84).
Insomnia. Insomnia severity was assessed by the Insomnia Severity Index (ISI) [37], vali-
dated in Brazil with good psychometric indicators (α = 0.86) [38]. The questionnaire consists
of seven items that evaluate severity of sleep onset, sleep maintenance and early morning
awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime func-
tioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. The
score for each item ranges from 0 to 4, for a total possible range of 0 to 28 points, with a higher
score indicating greater insomnia severity. Cronbach’s α of the scale in the current sample was
identical to that of the original validation study in Brazil (α = 0.86).
Anxiety. The State and Trait Anxiety Index (STAI) [39] has been validated in Brazil
(α = 0.87) [40]. The current study used only the trait anxiety subscale, which is less susceptible
to environmental alterations. This subscale is composed by 20 items on a four-point Likert
scale (“almost never”, “sometimes”, “often”, “almost always”), in which the participant is
asked, “How do you usually feel?”. Cronbach’s α in this sample was excellent (0.90).
Statistical analyses. For the descriptive analyses, we presented medians with interquartile
intervals (IQR), the amplitude of the distribution for the continuous data, and description of
the frequency for the categorical data (see Table 1).
We initially categorized the subscales of the BENDEP-SRQ-PV into binary variables to
increase the statistical power of the analyses. We carried out Generalized Linear Models
(GzLM) for the binary dependent variable (binomial regression) with binomial distribution
for all the BENDEP-SRQ-PV subscales. To choose the distribution, we used the lowest value
found for the Akaike Index Criteria (AIC) among the Poisson, binomial and negative binomial
models.
To assess primary study outcomes, we performed simple regressions containing outcome
variables (factors of the hypnotic dependence scale) and other variables that would be poten-
tially associated (mindfulness, anxiety, insomnia, schooling, income, age, type of hypnotic,
time of use and use under medical supervision). We then tested several binomial regression
models to evaluate the association between each of the BENDEP-SRQ-PV factors and associ-
ated variables as established in the simple regressions. The models were adjusted for variables
that might interfere in the use of hypnotics or in the comprehension of the questionnaires
(i.e., continuous variables: insomnia severity, age and anxiety; categorical variables: schooling
and income). Menopause was not included in the adjustment because it presented multicolli-
nearity with age. All regression models included only complete data. The minimum n included
in models was 68 participants, or 89.5% of the sample. The subscale “Whithdrawal” of the
Mindfulness and hypnotic dependence
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Table 1. Sociodemographic and hypnotics use characteristics (N = 76).
Median IQR Min-Max
Age group 50 15 25–85
Time using hypnotics (months) 30 51 3–264




Missing data 1 1.3
Lived with their children 35 46.7
Schooling n %
Incomplete to complete junior high 10 13.2
Incomplete to complete high school 19 25
Incomplete college to post-graduation 46 60.5
Missing data 1 1.3
Family Income per month2 n %
U$ 154–618 11 14.5
U$ 618–1545 29 38.2
U$ 1545–3090 17 22.4
More than U$ 3090 13 17.1
Missing data 6 7.9
Main income source of the family n %
No 37 48.7
Yes 36 47.4




Missing data 2 2.6
Medical supervision for the use of hypnotics n %
No supervision, use at their own risk 10 13.2
Yes 64 84.2
Missing data 2 2.6
The physician evaluates sleep or the deleterious effects of
hypnotics
n %
No, he/she only renews the prescription. 32 42.1
Yes 40 52.6
Missing data 4 5.3
Number of hypnotics used n %
1 67 88.2
2 or more 9 11.8
Ever tried to reduce or stop use n %
No 13 17.1
Yes 63 82.9
Hypnotic used1 Daily dose Min-
Max
n %
Diazepam 10-20mg 2 2.7
Lorazepam 1-4mg 5 6.7
Alprazolam 0.15-4mg 15 20
Clonazepam 0.1-10mg 29 38.7
(Continued)
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BENDEP-SRQ-PV only includes women who had tried to reduce the medication previously;
therefore, models including this variable had at least 58 of the 63 women that answered this
subscale, totaling 93.1% of this sample.
We performed analyses of normality of residuals based on qq plot graphs to evaluate the
quality of the final model. All the analyses were performed on the software STATA version
12, with the level of significance set at .05. According to the residual analysis by the qq plot
graphs of tested models, the residuals followed normal distribution, indicating the good model
quality.
Results
Characteristics of the sample
Descriptive analyses are included in Table 1. All participants (N = 76) were female, with
median age of 50 years (IQR = 15), and a majority had at least started college (60.5%).
Over a third reported a monthly income varying from (in U.S. dollars) $618.00 to $1,545.00
(38.2%) or from $1,545.00 to $3,090.00 (22.4%), and the income was shared among up to three
people in 85.3% of the cases. Only 20.5% of those women provided the household with the
total monthly income, that is, they were the main income source and, in 48.7% of the other
cases, some other person provided the household with the major income.
Concerning hypnotics, the median of age of onset of use was 48 years (IQR = 19), with con-
tinued use for 30 months (IQR = 51), and a minimum time of three months and maximum of
264 months. Regarding sites under which they had hypnotic use supervision, 57.3% received
service at a private physician’s office, 20% at a Basic Health Unit (UBS), 8.0% in hospitals
and 13.3% had no supervision. Of those with no supervision, 50% procured the medication
through an acquaintance or a physician in the family, 41.7% through friends or family mem-
bers, and 8.3% purchased it on the internet. Of those who were supervised, in 44.4% the physi-
cian did not evaluate the patient’s sleep or the possible deleterious effects of the long-term use
of the hypnotic.
Tables 2 and 3 describe the data outcome and predictive variables, respectively.
We performed binomial regression analyses (GzLM) with hypnotic type (BZD or Z drug)
as a predictor, and subscales of hypnotic dependence as outcomes, controlling for insomnia
severity, age, schooling, income, and trait anxiety. No significant differences emerged between
the two types of medication and risk of dependence subscales (Table 4).
In regression models with “Problematic Use” as an outcome, none of the facets of mindful-
ness were significantly associated with problematic use of hypnotics, neither in the crude nor
in the adjusted models. Regarding “Preoccupation”, often characterized by anticipatory anxi-
ety about non-use of medication, the observing facet and the total score of the FFMQ were sig-
nificantly and inversely associated with this subscale of the Bendep-SRQ-PV. (Table 4).
Table 1. (Continued)
Median IQR Min-Max
Zolpidem 0.25-40mg 31 41.3
Other3 1-15mg 4 5.3
1Percentage does not reach 100% because the variable yields more than a single response.
2A monthly minimum wage in Brazil corresponded to approximately US$ 309,00 by the time of the data collection.
3The other hypnotics used were Bromazepam, Cloxazolam, Chlordiazepoxide and Zopiclone
https://doi.org/10.1371/journal.pone.0194035.t001
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In models including only with the women who had attempted to reduce or discontinue
hypnotic use, FFMQ subscales “Observing” and “Non-Reactivity to inner experience” were
associated with lower scores on the subscale of harm resulting from withdrawal symptoms
(Table 4).
Finally, higher scores on the total FFMQ and in the facet “Non-Reactivity to inner experi-
ence” reduced the odds of a higher score in the “Lack of compliance” subscale of the Bendep-
SRQ-PV (Table 4).
Discussion
Results from this cross-sectional study revealed two main findings. First, contrary to hypothe-
ses, facets of mindfulness were not significantly associated with the awareness of problematic
use of hypnotics. However, aligned with hypotheses, some of the facets were inversely
Table 2. Descriptive data of the subscales of hypnotic dependence—Outcome variables.
Bendep-SRQ-PV subscales n %
Problematic use
Very low to moderate 11 14.7
High to very high 63 82.7
Missing data 2 2.7
Preoccupation n %
Very low to moderate 37 48.7
High to very high 36 47.4
Missing data 3 3.9
Lack of compliance n %
Low 31 40.8
High to very high 43 56.6
Missing data 2 2.6
Withdrawala n %
Low to very low 26 41.3
Moderate to high 37 58.7
a The n of this variable included only women who had already tried to reduce or stop the use of hypnotics (n = 63);
therefore, models including this variable had at least 58 of the 63 women that answered this subscale, totaling 93.1%
of this sample.
https://doi.org/10.1371/journal.pone.0194035.t002
Table 3. Descriptive data of the mindfulness facets, insomnia, and anxiety—Predictor variables.
Median IQR Min—Max
Insomnia severity 18 7 5–28
Total mindfulness 94.5 25 53–126
Non-judging of inner experience 26 11 8–39
Describing (items with positive formulation) 15 7 6–23
Describing (items with negative formulation) 12 5 3–15
Non-reactivity to inner experience 17 6.5 7–30
Acting with awareness (automatic pilot) 17 4.5 7–21
Acting with awareness (distraction) 10 6 3–15
Observing 24.5 9 10–39
Trait Anxiety 51 14 24–72
https://doi.org/10.1371/journal.pone.0194035.t003
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associated with specific aspects of dependence. Specifically, the mindfulness facets “Observing”
and “Non-Reactivity to inner experience”, in addition to the total score, were associated with
“Preoccupation with the lack of use”, “Lack of compliance with the therapeutic regimen” and
“Impairments caused by withdrawal symptoms when discontinuation is attempted”.
To our knowledge, this is the first study to evaluate the relation between dispositional
mindfulness and hypnotic dependence. The women interested in participating were
Table 4. Association between dispositional mindfulness, type of hypnotic and hypnotic dependence.
Problematic Use n Crude OR (95% CI) p n Adjusted OR (95%CI) p
Total FFMQ 68 0.98 (0.94–1.03) 0.458 60 1.00 (0.94–1.07) 0.848
Non-judging of inner experience 69 0.97 (0.89–1.07) 0.605 60 1.02 (0.87–1.20) 0.775
Describing (items with positive formulation) 70 0.99 (0.85–1.16) 0.947 61 1.02 (0.86–1.21) 0.817
Describing (items with negative formulation) 70 0.85 (0.66–1.08) 0.182 61 0.90 (0.66–1.23) 0.505
Non-reactivity to inner experience 70 0.98 (0.86–1.11) 0.697 61 0.96 (0.81–1.28) 0.601
Acting with awareness (automatic pilot) 70 0.99 (0.80–1.22) 0.914 61 1.07 (0.80–1.44) 0.636
Acting with awareness (distraction) 69 1.01 (0.83–1.23) 0.895 61 1.14 (0.89–1.45) 0.284
Observing 70 0.99 (0.89–1.09) 0.831 61 0.98 (0.86–1.11) 0.724
Type of hypnotic 73 1.26 (0.33–4.77) 0.730 62 3.12 (0.51–19.23) 0.219
Preoccupation n Crude OR (95% CI) p n Adjusted OR (95%CI) p
Total FFMQ 68 0.94 (0.90–0.97) 0.001 60 0.94 (0.89–0.99) 0.020
Non-judging of inner experience 69 0.90 (0.83–0.97) <0.01 60 0.90 (0.80–1.01) 0.085
Describing (items with positive formulation) 70 0.87 (0.77–0.97) <0.05 61 0.90 (0.79–1.02) 0.098
Describing (items with negative formulation) 70 0.87 (0.75–1.02) 0.082 61 0.81 (0.65–1.00) 0.056
Non-reactivity to inner experience 70 0.97 (0.88–1.06) 0.583 61 0.99 (0.87–1.12) 0.852
Acting with awareness (automatic pilot) 70 0.86 (0.74–1.01) 0.067 61 0.95 (0.77–1.17) 0.630
Acting with awareness (distraction) 69 0.86 (0.74–0.99) <0.05 61 0.92 (0.76–1.10) 0.340
Observing 70 0.89 (0.82–0.97) <0.01 61 0.87 (0.79–0.97) 0.011
Type of hypnotic 73 1.31 (0.52–3.35) 0.567 62 1.82 (0.57–5.84) 0.314
Withdrawal n Crude OR (95% CI) p n Adjusted OR (95%CI) p
FFMQ total 58 0.96 (0.93–1.00) 0.050 51 0.97 (0.91–1.03) 0.384
Non-judging of inner experience 58 0.95 (0.89–1.02) 0.185 51 1.05 (0.92–1.21) 0.446
Describing (items with positive formulation) 59 0.91 (0.81–1.03) 0.147 52 0.86 (0.73–1.02) 0.082
Describing (items with negative formulation) 59 1.00 (0.86–1.17) 0.974 52 1.03 (0.82–1.30) 0.807
Non-reactivity to the inner experience 59 0.91 (0.81–1.01) 0.084 52 0.78 (0.63–0.96) 0.021
Acting with awareness (automatic pilot) 59 0.91 (0.77–1.08) 0.270 52 1.05 (0.82–1.35) 0.667
Acting with awareness (distraction) 59 0.96 (0.82–1.12) 0.601 52 1.15 (0.90–1.47) 0.267
Observing 59 0.94 (0.87–1.02) 0.136 52 0.84 (0.73–0.97) 0.019
Type of hypnotic 62 0.93 (0.34–2.57) 0.894 53 0.62 (0.16–2.47) 0.500
Lack of compliance n Crude OR (95% CI) p n Adjusted OR (95%CI) p
Total FFMQ 69 0.95 (0.92–0.99) <0.01 61 0.94 (0.89–0.99) 0.025
Non-judging of inner experience 70 0.94 (0.88–1.00) 0.066 61 0.96 (0.86–1.07) 0.464
Describing (items with positive formulation) 71 0.94 (0.84–1.05) 0.275 62 0.93 (0.82–1.05) 0.245
Describing (items with negative formulation) 71 0.92 (0.79–1.07) 0.275 62 0.91 (0.74–1.11) 0.349
Non-reactivity to the inner experience 71 0.93 (0.84–1.02) 0.124 62 0.86 (0.75–0.99) 0.034
Acting with awareness (automatic pilot) 71 0.86 (0.72–1.01) 0.068 62 0.93 (0.75–1.15) 0.494
Acting with awareness (distraction) 70 0.92 (0.79–1.06) 0.238 62 0.94 (0.78–1.13) 0.502
Observing 71 1.04 (0.96–1.12) 0.306 62 1.04 (0.96–1.14) 0.326
Type of hypnotic 74 0.79 (0.31–2.02) 0.629 63 0.67 (0.21–2.12) 0.492
Models adjusted for insomnia severity, age, schooling, income, and anxiety.
https://doi.org/10.1371/journal.pone.0194035.t004
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characterized by higher educational level and income, representative of the intersection of
women who use hypnotics and those who are interested in mindfulness. A recent survey with
a representative U.S. sample on use of hypnotics between 2005 and 2010 detected that the
increase in the frequency of use of hypnotics was proportional to the increase in level of educa-
tion [41]. Similarly, the profile of people who searched for mindfulness training and resources
in the U.S. was composed of 61% of women who, when compared to non-meditators, were
more likely to have at least some college education, and 27% more likely to report having
insomnia [42]. It should be noted that, although most of our sample used hypnotics under pre-
scription and reported that their physicians evaluated the impact of the medication on their
sleep and/or its deleterious effects on their motor or cognitive functioning, 44.4% reported no
evaluation from a professional who renewed their prescription, supporting the chronic and
inappropriate use of the medication [43].
Of note, regression models with subscales of dependence as outcomes, adjusted for income,
age, schooling, anxiety and insomnia, yielded no significant differences between use of benzodi-
azepines and non-benzodiazepines (z drugs) on any of the dependence subscales. Although it is
not possible to state that dependence is similar between these two classes of hypnotics, our data
did not yield a significant difference between the individuals who use these two classes of medi-
cation. Previous studies have found evidence that chronic use of z drugs may lead to dose esca-
lation and heavy use, and that the renewal of prescriptions without a proper medical evaluation
is associated with a higher risk of dependence [44, 45]. These findings reinforce the importance
of including this class of medication in studies that evaluate chronic use of hypnotics.
Regarding our primary analyses assessing the relation between facets of mindfulness and
indices of dependence, none of the mindfulness facets showed a significant association with
“Problematic Use”. This might indicate that dispositional mindfulness does affect the aware-
ness of risks associated with chronic hypnotics use. These findings may be understood when
we consider that the majority of use was under prescription, and prescribed medications are
frequently believed to be safe, which may lead users to view use as non-problematic, or as not
involving risk [46]. A surprising finding was that the facets “Observing” and “Describing”
were not inversely associated with “Problematic Use”. These mindfulness subscales describe
the perception and description of present-moment inner experiences, such as sensations, cog-
nitions, and emotions. Users of hypnotics may favor awareness of the acute effect of use on
their body over other perceptual experiences [19]. Acknowledging problematic use demands
an understanding of the impact of the medication over time, skills that should be developed by
other interventions, such as psychoeducation or motivational interviewing, as observed in pre-
vious studies with this population [11, 47, 48].
Considering the current study’s focus on the anticipation components of dependence, rep-
resented by the subscales “Preoccupation” and “Lack of compliance”, it is notable that the total
mindfulness score and the “Observing” facet were the primary protective factors against higher
scores on the subscale “Preoccupation”, even after the adjustment of the models. Our findings
are in line with previous studies that identified skills of attention and awareness, as measured
by the subscale “Observing”, as vital to relapse prevention, when included with the other mind-
fulness skills of non-judgment, non-reactivity and focused action, comprising the total FFMQ
score in populations without experience in meditation [19], as was the case with our sample
[17]. Concerning the subscale “Lack of compliance”, the total mindfulness score and the facet
“Non-reactivity to inner experience” were the only scores that remained significant after the
adjustment of the model as protective factors against higher scores in this subscale. This might
suggest the importance of awareness and non-reactivity when facing discomfort, fostering dif-
ferent choices, breaking the vicious circle between trigger and substance use, as observed in
previous studies that tested this relation [25].
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Finally, the mindfulness facets “Observing” and “Non-Reactivity to inner experience” were
the only facets that remained significant after the adjustment as potential protective factors
against higher scores on the “Withdrawal” scale. It has been suggested that mechanisms
through which mindfulness skills might benefit health are not related to the change in the
experience itself, but to the change in one’s relation to experiences, i.e., with a more accepting
and open perspective [26]. A recent study demonstrated that “non-reactivity” moderated the
effect of “Observing” on the symptoms of anxiety and thought rumination, increasing the use
of more adaptive strategies of emotional regulation and reducing maladaptive strategies, such
as suppression. Therefore, indirect effects of “Observing” in each symptom grew stronger as
“Non-reactivity” increased [35]. Consequently, our results indicate that even though with-
drawal symptoms occur upon removal of the hypnotic, women scoring higher on observing
and not reacting to symptoms also had a lower score in the subscale of perception of impair-
ments induced by withdrawal.
Broadly speaking, results from the present study corroborate previous findings with differ-
ent clinical conditions, indicating that dispositional mindfulness is negatively associated with
habitual negative thoughts [49] and experiential avoidance [50], in the same way that individu-
als who present higher levels of mindfulness tend to have the inherent ability to observe their
thoughts with detachment, without adhering or reacting to them as if they were an absolute
truth, but rather as transient mental events [51].
Strengths and limitations
Among the strengths of this study, one to be highlighted is the novelty of our findings.
Although studies on related topics are common, such as mindfulness and other substances of
dependence [22] and mindfulness and insomnia [20], we did not find any studies in the litera-
ture that evaluated the relation between dispositional mindfulness and chronic hypnotic use,
despite the fact that it is highly prevalent and known to be associated with several issues [3].
Moreover, our findings support the importance and need of further studies on non-pharmaco-
logical approaches to the current population, once the lack of this treatments seems to be an
important reason to the maintenance of chronic use [8].
Additionally, the instruments used to measure the primary study variables, hypnotic depen-
dence and mindfulness, are multidimensional, promoting a better understanding of which
aspects of dependence are potentially mitigated by specific mindfulness skills. The FFMQ is
one of the main instruments used worldwide to evaluate mindfulness, having been validated
in several countries, including Brazil [34], promoting the replication of the study in different
populations.
The primary limitation of the study is its cross-sectional design, preventing inference of
causality. Another limitation to consider is bias in the sample. Participation in the study was
not through referral from the medical services, widely known for the high number of hypnotic
prescriptions, but through media broadcast about a longitudinal clinical trial. Consequently,
caution should be used in generalizing results, since the recruitment methods might have
attracted individuals who are more aware of their health condition and/or more interested in
mindfulness. Another consideration is use of self-report measures, which may be influenced
by social desirability, or subject to mistaken interpretations of the content of questions. Finally,
the small sample size increases likelihood of Type II error.
Previous studies with similar populations have demonstrated that integrative and group
psychotherapeutic strategies, which consider coexisting psychiatric symptoms such as anxiety
and insomnia, are useful to individuals in the process of gradual hypnotics tapering [52].
Hence, to further explored results from the current study, and to broaden therapeutic options
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for this population, further studies with larger samples and/or longitudinal designs evaluating
the impact of mindfulness interventions in this population are warranted.
Conclusion
This is the first study, to our knowledge, to provide data on the relation between disposi-
tional mindfulness and hypnotic dependence among women. Select mindfulness facets were
associated with the dimensions of dependence that involve (1) the anticipatory cognitive
component related to the possible unavailability of the medication; (2) the compulsive com-
ponent of using the medication beyond medical prescription, also related to the anxiety of
suffering from the symptoms in case the dose indicated does not yield the expected results,
and (3) perception of the harm caused by withdrawal symptoms in the event of reduction or
withdrawal of the hypnotic. This suggests that dispositional mindfulness was associated with
milder levels of dependence and suffering caused by withdrawal symptoms, but not necessar-
ily with the acknowledgment of risks and problematic use. These findings stress the impor-
tance of considering positive psychological factors in studies on dependence and chronic use
of hypnotics.
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